+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Chronic Obstructive Pulmonary Disease - US Access & Reimbursement

  • ID: 4705766
  • Report
  • December 2017
  • Region: United States
  • 196 pages
  • Decision Resources Group
1 of 3


This Chronic Obstructive Pulmonary Disease market Access & Reimbursement report provides brand-level insight regarding the impact of payer policy on physician prescribing behavior in the Chronic Obstructive Pulmonary Disease market so you can optimize your market access strategy and determine how to best position your brand to specific stakeholders.

This report includes specific detail on the Chronic Obstructive Pulmonary Disease market access trends for a disease in a given region, insight on how to maximize opportunity and limit barriers, analysis of key reimbursement decision-makers and the criteria they use, review of market access strategies used by competitors and highlights of where they succeeded or stumbled, detailed analysis of physician and payer perceptions based on over five thousand physician surveys and over a thousand in-depth interview with payers each year, and much more. This report is most relevant for professionals in market research, business intelligence, market access, brand teams, launch planning teams, business development & licensing. This report was published in December 2017.
Note: Product cover images may vary from those shown
2 of 3


1. Detailed, Expanded Analysis (US)
2. Market Access Overview
3. Actionable Recommendations to Optimize Market Access
4. Successes and Stumbles
5. Key Stakeholders in the Road to Market Access
6. Key Market Access Roadblocks
7. Reimbursement Dynamics
8. Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
9. Market Access Landscape for Emerging Therapies.
10. Methodology
11. Appendix
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Pfizer
  • Eli lilly
Note: Product cover images may vary from those shown